Figure 3
Figure 3. CD4+ T cells activated by AgAb treatment can kill target LCLs. A 4-hour 51Cr-release cytotoxicity assay was performed. LCLs were either untreated (medium only) or treated with 1 μg EBNA3C 3H10 peptide (corresponding to 5 μg/mL), 10 ng or 1 ng antibodies (corresponding to 50 ng/mL or 5 ng/mL of αCD20, αCD19, αCD21, and αCD22) containing the EBNA3C 3H10 epitope, or 10 ng antibody without epitope (corresponding to 50 ng/mL) for 24 hours. LCLs were then incubated with CD4+ T cells specific to the EBNA3C 3H10 epitope for 4 hours at varying E:T ratios. Cell lysis was determined by 51Cr release. All assays were performed in triplicate and means and standard deviations are shown.

CD4+ T cells activated by AgAb treatment can kill target LCLs. A 4-hour 51Cr-release cytotoxicity assay was performed. LCLs were either untreated (medium only) or treated with 1 μg EBNA3C 3H10 peptide (corresponding to 5 μg/mL), 10 ng or 1 ng antibodies (corresponding to 50 ng/mL or 5 ng/mL of αCD20, αCD19, αCD21, and αCD22) containing the EBNA3C 3H10 epitope, or 10 ng antibody without epitope (corresponding to 50 ng/mL) for 24 hours. LCLs were then incubated with CD4+ T cells specific to the EBNA3C 3H10 epitope for 4 hours at varying E:T ratios. Cell lysis was determined by 51Cr release. All assays were performed in triplicate and means and standard deviations are shown.

Close Modal

or Create an Account

Close Modal
Close Modal